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drug studies but it is crucial to realise that gametocytaemia is a weak
surrogate marker of mosquito infectivity. Gametocyte density has
been shown to correlate withmosquito infectivity in untreated individ-
uals in a non-linear relationship (Jeffery and Eyles, 1955) (Churcher et
al., 2012). Post treatment, the relationship is more difﬁcult to deﬁne
(Beavogui et al., 2010) but Dicko et al. found no relationship followingIn this issue of EBioMedicine, Okebe et al. have published a paper
from The Gambia on the antigametocyte effects of three doses (0.2,
0.4 & 0.75 mg base/kg body weight) of single dose primaquine (PQ)
combined with dihydroartemisinin piperaquine (DHAPP) in asymp-
tomatic carries of P. falciparum, a key target group for malaria elimina-
tion (Okebe et al., 2016). They included individuals aged at least one
year without symptoms or fever who: (i) were carriers of Plasmodium
falciparum (detected by slide microscopy), (ii) did not have glucose-6-
phosphate dehydrogenase deﬁciency as detected by the ﬂuorescent
spot test, and (iii) had haemoglobin (Hb) concentrations of ≥8 g/dL.
DHAPP was dosed on study days (D) 0, 1 and 2 and PQ delayed ≥1 h
after the last DHAPP dose. The primary end point was D7 gametocyte
carriage, determined by quantitative nucleic acid sequence-based am-
pliﬁcation of Pfs25mRNA female gametocytes. Secondary end points in-
cluded mosquito infectivity on D7, assessed by membrane feeding
assays (MMFAs), and the decline in Hb concentrations.
This study is one of several studies from a consortium that are
assessing/have assessed the antigametocyte efﬁcacy and the transmis-
sion blocking effects of PQ. Like the study of Goncalves et al., Okebe et
al. have included an assessment of mosquito infectivity in a subset
(Goncalves et al., 2016).
This study showed that all PQ doses produced marked and similar
declines in gametocyte carriage on D7 and D14 and that these declines
were signiﬁcantly greater than DHAPP alone. A chi-squared for trend
was signiﬁcant for a dose dependent effect on D7. The ﬁnal sample
size was insufﬁcient to demonstrate non-inferiority of either the 0.2 or
0.4 mg/kg PQ arms vs. the 0.75 mg/kg dose (the dose ﬁrst recommend-
ed byWHO) but this is not a limitation. The high efﬁcacy of all three PQ
doses suggests that the 0.2 mg/kg dose is already high on the PQ dose
response curve for gametocytocidal effects.m.2016.10.032.
en access article under the CC BY-NCGametocyte carriage has been an efﬁcacy end point in antimalarial
treatment with PQ combined with DHAPP (Dicko et al., 2016).
Okebe et al.'s study has reconﬁrmed the ﬁndings fromGoncalves et al.
that mosquito infectivity is low in individuals with low gametocytaemias
who have been treatedwith an artemisinin based combination treatment
(ACT)with orwithout PQ. Both studies used the sameMMFAprotocol but
performing MMFAs is challenging. They require optimal conditions to
maintain healthy mosquitoes, are less sensitive than direct mosquito
feeding andmeasure infectivity at one time point. Moreover, the number
of mosquitoes used by Okebe et al. was low, lower than that of Goncalves
et al., and considerably lower than the numbers used by Dicko et al. Thus,
they may have underestimated infectivity in all the treatment arms. One
limitation is the lack of a baseline infectivity assessment so a treatment ef-
fect cannot be quantiﬁed.
The tolerability of these PQ doses, dosed at 48 h, in otherwise
healthy, G6PD normal individuals with adequate Hb concentrations
was, as expected, good. D3 was the day of the nadir Hb concentration
and most of the declines in the D3 Hb concentrations would have
been malaria related. The Hb dynamics between these asymptomatic
individuals and patients with acute uncomplicated falciparum malaria
overlap – a point that may not be widely appreciated.
Where do these results leave us regarding future research and policy?
Okebe et al.'s trial was not designed to assess PQ safety in G6PD de-
ﬁcient individuals. Themain PQ related toxicity feared by policymakers
in such individuals is acute haemolytic anaemia. However, safety data
on single low dose (SLD) PQ dosed at 0.25 mg/kg in asymptomatic/
well individuals are accumulating and are reassuring. In Thailand,
mean Hb declines of ~–5% and ~–1% were seen in G6PD deﬁcient and
normal individuals, respectively, when SLDPQ was given with DHAPP
as mass drug administration (Bancone et al., 2016). The SAFEPRIM I
and II studies have been completed in Africa and are not yet published.
The indications are that there are no safety signals but more work is
needed to include anaemic children and adults.
The knowledge gap that demands an adequately powered trial is the
safety of SLDPQ in children with acute uncomplicated malaria when-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Such a trial, that has few exclusion criteria to maximise its
generalisability, is planned for 2017 under the sponsorship of Oxford
University.
Low infectivity was found in these low gametocytaemic, asymptom-
atic individuals on D7. The trial was not designed nor powered to
answer the question whether PQ combined with DHAPP increases the
anti-infectivity efﬁcacy in such individuals nor do we know how infec-
tious these individualswere at baseline. Goncalves et al. found apprecia-
ble pretreatment infectivity in their study but they recruited
asymptomatic individuals with patent gametocytaemia.
To determine the optimal PQ dose in asymptomatic P. falciparum
carriers, a large, dose-ranging trial would be needed with mosquito in-
fectivity as the efﬁcacy end point. Alternatively one could simply assess
the WHO recommended SLDPQ dose of 0.25 mg/kg looking for an
“added value” of PQ. It is very unlikely that PQ will achieve complete
transmission blocking but if it achieves “high” efﬁcacy and adds value
over an ACT alone, it would be an attractive option for malaria
elimination.
Disclosure
The author declared no conﬂicts of interest.
References
Bancone, G., Chowwiwat, N., Somsakchaicharoen, R., Poodpanya, L., Moo, P.K.,
Gornsawun, G., Kajeechiwa, L., Thwin, M.M., Rakthinthong, S., Nosten, S., Thinraow,S., Nyo, S.N., Ling, C.L., Wiladphaingern, J., Kiricharoen, N.L., Moore, K.A., White, N.J.,
Nosten, F., 2016. Single low dose primaquine (0.25 mg/kg) does not cause clinically
signiﬁcant haemolysis in G6PD deﬁcient subjects. PLoS One 11 (3), e0151898.
Beavogui, A.H., Djimde, A.A., Gregson, A., Toure, A.M., Dao, A., Coulibaly, B., Ouologuem, D.,
Fofana, B., Sacko, A., Tekete, M., Kone, A., Niare, O., Wele, M., Plowe, C.V., Picot, S.,
Doumbo, O.K., 2010. Low infectivity of Plasmodium falciparum gametocytes to Anoph-
eles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int.
J. Parasitol. 40 (10), 1213–1220.
Churcher, T.S., Blagborough, A.M., Delves, M., Ramakrishnan, C., Kapulu, M.C., Williams,
A.R., Biswas, S., Da, D.F., Cohuet, A., Sinden, R.E., 2012. Measuring the blockade of ma-
laria transmission–an analysis of the standard membrane feeding assay. Int.
J. Parasitol. 42 (11), 1037–1044.
Dicko, A., Brown, J.M., Diawara, H., Baber, I., Mahamar, A., Soumare, H.M., Sanogo, K., Koita,
F., Keita, S., Traore, S.F., Chen, I., Poirot, E., Hwang, J., McCulloch, C., Lanke, K., Pett, H.,
Niemi, M., Nosten, F., Bousema, T., Gosling, R., 2016. Primaquine to reduce transmis-
sion of Plasmodium falciparummalaria in Mali: a single-blind, dose-ranging, adaptive
randomised phase 2 trial. Lancet Infect. Dis. 16 (6), 674–684.
Goncalves, B.P., Tiono, A.B., Ouedraogo, A., Guelbeogo, W.M., Bradley, J., Nebie, I., Siaka, D.,
Lanke, K., Eziefula, A.C., Diarra, A., Pett, H., Bougouma, E.C., Sirima, S.B., Drakeley, C.,
Bousema, T., 2016. Single low dose primaquine to reduce gametocyte carriage and
Plasmodium falciparum transmission after artemether-lumefantrine in children with
asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC
Med. 14, 40.
Jeffery, G.M., Eyles, D.E., 1955. Infectivity to mosquitoes of Plasmodium falciparum as relat-
ed to gametocyte density and duration of infection. Am.J.Trop. Med. Hyg. 4 (5),
781–789.
Okebe, J., Bousema, T., Affara, M., et al., 2016. The gametocytocidal efﬁcacy of different sin-
gle doses of primaquine with dihydroartemisinin-piperaquine in asymptomatic par-
asite carriers in the Gambia: a randomized controlled trial. EBioMedicine 13,
348–355.
